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Abstract
Background: Mycobacterium tuberculosis Region-of-Difference-1 gene products present opportunities for specific diagnosis
of M. tuberculosis infection, yet immune responses to only two gene-products, Early Secretory Antigenic Target-6 (ESAT-6)
and Culture Filtrate Protein-10 (CFP-10), have been comprehensively investigated.
Methods: T-cell responses to Rv3873, Rv3878 and Rv3879c were quantified by IFN-c-enzyme-linked-immunospot (ELISpot)
in 846 children with recent household tuberculosis exposure and correlated with kinetics of tuberculin skin test (TST) and
ESAT-6/CFP-10-ELISpot conversion over six months and clinical outcome over two years.
Results: Responses to Rv3873, Rv3878, and Rv3879c were present in 20–25% of contacts at enrolment. Rv3873 and Rv3879c
responses were associated with and preceded TST conversion (P=0.02 and P=0.04 respectively), identifying these antigens
as early targets of cell-mediated immunity following M. tuberculosis exposure. Responses to Rv3873 were additionally
associated with subsequent ESAT-6/CFP-10-ELISpot conversion (P=0.04). Responses to Rv3873 and Rv3878 predicted
progression to active disease (adjusted incidence rate ratio [95% CI] 3.06 [1.05,8.95; P=0.04], and 3.32 [1.14,9.71; P=0.03],
respectively). Presence of a BCG-vaccination scar was associated with a 67% (P=0.03) relative risk reduction for progression
to active tuberculosis.
Conclusions: These RD1-derived antigens are early targets of cellular immunity following tuberculosis exposure and T-cells
specific for these antigens predict progression to active tuberculosis suggesting diagnostic and prognostic utility.
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Introduction
Eradication of tuberculosis in low- and intermediate-burden
regions hinges on the accurate diagnosis and treatment of latent
tuberculosis infection (LTBI) [1,2]. The advent of interferon-c
release assays (IGRAs) is a significant advance in the diagnosis of
M. tuberculosis infection [3,4]. The chief advantage of IGRAs over
the tuberculin skin test (TST) is their high specificity for M.
tuberculosis infection [5,6,7,8,9,10,11] which stems from the
genomic origins of the antigens they use: early secretory antigenic
target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10). Both
gene products are encoded in Region of Difference-1 (RD1), a
genomic segment present in M. tuberculosis complex but absent
from all strains of BCG and most environmental mycobacteria
[12,13,14,15].
T-cell responses to these antigens are prognostic of progression
to active tuberculosis disease but from the few longitudinal cohort
studies published to date there is no clear consensus as to whether
the prognostic power of current ESAT-6/CFP-10-based IGRAs is
significantly greater than the TST [16,17,18,19,20,21,22,23,24].
Development of a biomarker with higher predictive power than
TST for progression to active tuberculosis is a global public health
priority as it would greatly reduce the number of contacts that
need to be treated to prevent each case of active disease
[25,26,27,28]. Progress towards such a biomarker requires
investigation of immune responses to a broad range of candidate
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clinical outcomes prospectively over time; however, no longitudi-
nal studies have investigated antigens other than those in the
commercial IGRAs: ESAT-6, CFP-10 and, in the case of
Quantiferon-Gold-In tube, Rv2654.
The remaining RD1-encoded gene products share the same
species distribution as ESAT-6 and CFP-10, are highly specific for
M. tuberculosis complex but have been little-investigated to date
[29,30,31,32,33,34,35,36,37]. The limited available data derived
from cross-sectional studies in active tuberculosis disease and
BCG-vaccinated unexposed controls indicate that interferon-c
(IFN-c) T-cell responses to these antigens have high specificity
(97.4%–100%) and low-to-moderate sensitivity (25.5%–53.1%) for
active tuberculosis, after exclusion of cross-reactive peptides
encoded in conserved motifs of Rv3873 [30,35,37]. Given their
location in the M. tuberculosis genome and their high specificity in
tuberculosis-unexposed controls, responses to these antigens in
LTBI are of considerable interest. Whether they are targeted by
early T-cell responses after recent tuberculosis exposure and
whether these responses correlate with clinical outcomes over time
are important questions for advancing our understanding of how
M. tuberculosis-specific cellular immunity evolves after exposure and
for development of better biomarkers of LTBI.
We therefore investigated T-cell responses to Rv3873, Rv3878
and Rv3879c after tuberculosis exposure and correlated responses
with progression to active tuberculosis disease and established
markers of recent infection, i.e. TST conversion and ESAT-6/
CFP-10-ELISpot conversion, in a well-characterized cohort of
children with a very low prevalence of HIV infection and recent
household tuberculosis exposure [17,38,39].
Materials and Methods
Ethics Statement
Four-hundred forty-three adults with sputum smear-positive
pulmonary tuberculosis in the Istanbul government tuberculosis
service during the 20-month enrolment period with $1 child
household contact gave written informed consent on behalf of the
children and 1,024 child contacts aged #16 years were enrolled at
Marmara University Hospital [38].
Ethical approval was granted by the Institutional Review Board
of Marmara University Hospital, The Turkish Ministry of Health
and the World Health Organization Steering Committee on
Research Involving Human Subjects.
Clinical evaluation and follow-up
All children had a medical history, physical examination,
documentation of BCG-vaccination scars, TST and chest-radiog-
raphy and 1,020 gave a 10 mL blood sample. Initial venesection for
ELISpot and inoculation of PPD for TST were performed on the
same day for 1,007 of these children during the 20-month period
beginning October 2002. All assays were performed during this
period. In accordance with national guidelines, all children are
BCG-vaccinated aged two-three months and again at six-seven
years old. BCG coverage in children in Turkey was 79% in 2004
[38,40]. No children underwent repeat BCG vaccination during the
course of the study. All contacts were invited for clinical follow-up
six-monthly for two years, and parents advised to return with the
child for assessment if intercurrent symptoms developed.
Six-months isoniazid preventive therapy (IPT) was given in
accordance with national guidelines [41] to children ,6-years old;
children $6-years old with a positive TST or converted second
TST. Parents or guardians, who were provided with tablets at 2
monthly intervals, administered isoniazid to their children. We
questioned all parents or guardians who returned for follow-up
about adherence to preventive treatment, and all reported full
adherence [17].
Case definitions
Study pediatricians, blinded to the ELISpot results, diagnosed
incident tuberculosis on the basis of clinical, radiologic, and
microbiological criteria (see Materials and Methods S1) [17].
Tuberculin skin test
TST using the Mantoux method and two tuberculin units
purified protein derivative (PPD) RT23 was administered and read
by study pediatricians (blinded to ELISpot results) (see Materials
and Methods S1). For our analysis, TSTs were scored positive
where induration was $5 mm [17,42]. TST-negative contacts had
a repeat TST two-six months later to identify TST conversion,
defined as an increase of $10 mm [42].
ELISpot assays
These were performed and read by persons blind to personal
identifiers and TST results as described [38]. Pairs of duplicate
wells (2?5610
5 peripheral blood mononuclear cells [PBMCs] per
well) contained: positive (mitogen) and negative (no stimulus)
controls, streptokinase-streptodornase, PPD and 1 of 14 peptide-
pools incorporating 15-mer peptides spanning the length of
ESAT-6 (n=17), CFP-10 (n=18), or selected sequences [30]
from Rv3873 (n=12), Rv3878 (n=14) and Rv3879c (n=17).
Previously-described non-specific peptides from Rv3873 were ex-
cluded [30]. The ESAT-6/CFP10-peptide assay was subsequently
commercialized into the regulatory-approved T-SPOT.TB (Oxford
Immunotec, Oxford, United Kingdom). Wells were scored as
previously described [38]. ELISpot assays were repeated six months
post-recruitment (Materials and Methods S1). Repeat assays
prioritized the use of the conventional antigens and hence due to
lack of PBMCs only ESAT-6/CFP-10 peptide pools were included.
Statistical analysis
We defined each child’s entry into the study as the date first
examined and tested with ELISpot and TST; the end-point was
development of active tuberculosis or the last follow-up assessment
(whether by telephone or clinic visit). All analysis was based on
results obtained from assays done at the time of the original study.
Differences between proportions of contacts responding to each
antigen were compared using McNemar’s test for paired binary
variables. The magnitude of antigen-specific T-cell responses
amongst responders was compared using Wilcoxon matched-pairs
test for continuous variables. We used Poisson regression to
estimate incidence rates of progression to tuberculosis per 1000
person-years follow-up, with 95% confidence intervals (CIs). We
estimated incidence rate ratios to compare the prognostic value of
test-positive with test-negative results, both unadjusted and
adjusted for IPT. The relative risk (RR), with 95% CIs, was
calculated for TST and ELISpot conversion. We did all analyses in
Stata, v9.1 (StataCorp, College Station, Texas).
Results
Demographic and clinical characteristics of participants
Of 1024 children enrolled, 846 were confirmed household
contacts of adults with sputum smear-positive pulmonary tuber-
culosis with complete demographic, TST and ELISpot data for all
antigens available at recruitment (Figure 1). These 846 children
with a median age of 90 months (IQR 48 to 132), were contacts of
401 index patients living in 382 separate households, with 18
T-Cell Markers of TB Progression
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positive pulmonary tuberculosis. 50.5% were male, and the
average number of contacts per household was 2.4. Six-hundred
seventy-nine contacts (80%) had a BCG scar.
The study cohort of 846 child contacts was followed for 1125
person-years with a mean duration of 1.04 years follow-up
(range:0.25 to 3.28 years). Six-hundred and five children received
IPT. Fifty-seven children were lost to further follow-up after
clinical assessment at six months; withdrawal rates did not differ
according to ESAT-6/CFP-10 ELISpot status (6% of contacts
with positive ELISpot results vs 7% with negative results).
Fourteen contacts (1.7%) developed active tuberculosis disease
during the follow-up period. Sixty-four percent of contacts who
progressed to active disease were female, with a median age of 49
months (range:4to 177) [17]. Eight (57%) had BCGscars compared
with 671 of the 832 (81%) (P=0.03, Chi-square test) who did not
progress to tuberculosis (RR=67% (95% CI: 7%–88%). All 14
incident cases were asymptomatic with normal chest radiography at
enrolment and had no past history of active tuberculosis. Of the 12
incident cases started on IPT at enrolment, six developed active
tuberculosis beforecompleting thecourseandthreewereexposed to
index cases with multi-drug resistant tuberculosis [17]. Twelve
patients developed pulmonary tuberculosis and two developed
miliary disease [17]. The median time from recruitment to
progression to active disease was six months (range:4 to 25).
Although only three of 14 cases were culture-confirmed, all had
definitive clinical and radiological diagnoses, an appropriate
response to anti-tuberculosis treatment and remained well for .1
year after treatment completion [17].
Hierarchy of immunodominance of the RD1-encoded
antigens
The T-cell responses to Rv3873, Rv3878, Rv3879c, ESAT-6
and CFP-10 for each contact are presented in Figure 2. Sign-
ificantly more contacts had responses to CFP-10 (P,0.001) and
ESAT-6 (P,0.002) than to any of the novel antigens. Fewer
contacts mounted a T-cell response to Rv3878 than any other
antigen (P,0.001 in all cases) and the proportion of contacts with
T-cell responses to Rv3873 and Rv3879c did not significantly
differ from each other.
Comparing the number of IFN-c-spot forming cells for each
antigen, CFP-10 responses were significantly greater than responses
to any other antigen (P,0.02 in all cases). The T-cell response
specific for ESAT-6 was significantly greater compared to the novel
antigens (P,0.001 in all cases).
T-cell responses to RD1-encoded antigens after recent
tuberculosis exposure precede and predict TST
conversion
Three-hundred thirty-one (39.1%) child household contacts
exhibited a negative TST result at the time of recruitment. Three-
Figure 1. Study flow diagram. *The final study cohort of 846 child contacts with complete data on responses to all tested antigens was followed
for 1125 person-years (mean duration: 1.04 years follow-up [range 0.25 to 3.28 years]). Fifty-seven children were lost to further follow-up after clinical
assessment at six months; 256 children completed 24 months follow-up with six-monthly clinical reviews and 519 children were followed every six
months by standardized health status telephone questionnaire administered to parents and guardians by the study nurse after the first 12 months of
six-monthly clinical reviews.
{Two contacts were removed due to loss of the ELISpot plates and thirty-three contacts were removed due to an episode
of bacterial contamination of peptide pool reagents [38].
doi:10.1371/journal.pone.0028754.g001
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TST two to six months later (237 [76%] of which were done
within four months) and 41 (13%) of these became TST-positive.
TST-negative contacts with a T cell response to Rv3873, Rv3879c
or PPD at recruitment were significantly more likely to become
TST-positive at the time of the second TST (Table 1).
T-cell responses to Rv3873 after recent tuberculosis
exposure precede and predict ESAT-6/CFP-10 specific
IFN-c ELISpot conversion
Four-hundred eighty-six (57%) contacts had no detectable IFN-c
T-cell response to ESAT-6/CFP-10 at recruitment. Three-hundred
eighty seven (80%) of these initially ESAT-6/CFP-10-negative
contactshadarepeat ELISpotcarried out five tosevenmonthspost-
recruitment, by which time-point 59 (15%) exhibited an ESAT-6/
CFP-10-specific T-cell response.
Contacts with no baseline response to ESAT-6/CFP-10 who
had T-cell responses to Rv3873 (n=32) were significantly more
likely to develop an ESAT-6/CFP-10-specific T-cell response by
the time of the second ELISpot (relative risk of conversion 2.22
(95% CI 1.03, 4.81) P=0.04), suggesting that Rv3873 is an earlier
target of M. tuberculosis-specific T-cells after M. tuberculosis exposure
than ESAT-6/CFP-10. Baseline T-cell responses to Rv3878,
Rv3879c, PPD and SKSD as well as TST results were not
significantly associated with development of ESAT-6/CFP-10 T-
cell responses six months later (data not shown).
Baseline responses to the novel RD1-encoded antigens
detect potentially infected contacts who did not respond
to ESAT-6/CFP-10
After taking ESAT-6/CFP-10 responses into account, responses to
Rv3873, Rv3878 and Rv3879c identified 54 (6.4%) further contacts as
infected with M. tuberculosis at recruitment (P,0.001, McNemar’s test).
Figure 2. Magnitude of IFN-c T-cell responses to each RD1-
encoded antigen among responders to each antigen. The
median (inter-quartile range) of antigen-specific T-cells in individuals
who had a positive ELISpot response to ESAT-6, CFP-10, Rv3873, Rv3878
and Rv3879c were: 104 (38, 274.5), 133 (55.5, 348.5), 52 (30.5, 110), 62
(30, 124) and 64 (32, 115.5) per million PBMCs respectively. Significantly
more contacts had T-cell responses to CFP-10 (P,0.001) and ESAT-6
(P,0.002) than to any of the novel antigens. Fewer contacts mounted a
T-cell response to Rv3878 than any other antigen (P,0.001 in all cases)
and the proportion of contacts with T-cell responses to Rv3873 and
Rv3879c did not significantly differ from each other. CFP-10 responses
were significantly greater than responses to any other antigen (P,0.02
in all cases). The peptide-specific IFN-c-secreting T-cell response specific
for ESAT-6 was significantly greater compared to the RD1-derived novel
antigens (P,0.001 in all cases).
doi:10.1371/journal.pone.0028754.g002
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contacts were identified as being infected with M. tuberculosis.
T-cell responses to Rv3873 and Rv3878 after M.
tuberculosis exposure predict progression to active
disease
Of 210 contacts with positive IFN-c T-cell responses to Rv3873
at recruitment, seven (3.3%) progressed to active tuberculosis and
of 169 contacts with responses to Rv3878, six (3.6%) progressed.
Responses to each of these individual antigens predicted pro-
gression to active tuberculosis on unadjusted and adjusted
analyses (Table 2). Responses to either ESAT-6 or CFP-10 each
detected eight incident cases, but from a larger group of positive
responders. Predictive values of responses to ESAT-6 or CFP-10
were of borderline statistical significance at the 5% level on
adjusted analysis only (Table 2). T-cell responses to PPD and
SKSD at recruitment were not significantly associated with
progression to active disease (Table 2). Although responses to
Rv3873 identified a similar number of incident cases to ESAT-6
and CFP-10, a significantly lower proportion of contacts had
positive responses to Rv3873 (210/846) than to ESAT-6 (272/
846; p=0.013) or CFP-10 (296/846; p=0.001).
Ten incident cases had a positive response to ESAT-6/CFP-10
at recruitment; seven also responded to Rv3873, six to Rv3878
and five to Rv3879c. None of the incident cases had a positive
response to Rv3873, Rv3878 or Rv3879c that did not also have a
response to ESAT-6/CFP-10. Of the 360 contacts with a positive
ELISpot response to ESAT-6/CFP-10, 10 progressed to active
tuberculosis within 511 person years of follow-up (incidence rate,
19.6 per 1000 person years [95% CI, 9.3 to 36.0 per 1000 person-
years]). Three hundred and thirty-four (93%) of these children,
which includes all 10 incident cases, received IPT. On adjusted
analysis, children with a positive ESAT-6/CFP-10 ELISpot result
were 3.91 times more likely than those with a negative result to
develop active disease (95% CI 1.20, 12.74, P=0.02).
Discussion
This cohort of children with household exposure to infectious
pulmonary tuberculosis enabled, for the first time, investigation of
T-cell responses to novel RD1-encoded antigens in a population
of recently exposed individuals. Our findings identify these
antigens as early targets of cellular immunity following exposure
to M. tuberculosis. IFN-c-secreting T-cells specific for these antigens
had faster kinetics than established markers of recent M. tuberculosis
infection and predicted progression to active tuberculosis.
With no gold standard test for LTBI, progression to active
disease is the only way to confirm M. tuberculosis infection and is
essential for defining the clinical utility of new biomarkers of
LTBI. Baseline T-cell responses specific for Rv3873 and Rv3878
significantly predicted progression to active tuberculosis, indicat-
ing that the T-cell responses to these novel antigens are not only
specific, but also prognostic of M. tuberculosis infection. These are
the first antigens, other than those used in the commercial IGRAs,
to be identified as having prognostic value. Moreover, only one
other study has dissected the prognostic power of T-cell res-
ponses to the individual antigens contained in IGRAs: Leung
et al found that IFN-c-ELISpot responses to CFP-10 and not
ESAT-6 were predictive of progression to tuberculosis in silico-
tic adults without recent tuberculosis contact [21]. In our study,
the prognostic power of ELISpot responses to CFP-10, ESAT-
6, Rv3873 and Rv3878 were broadly similar on multivariate
analysis. Interestingly, responses to Rv3873 were significantly
more specific for progression to active tuberculosis compared to
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low sensitivity of the T-cell response to these antigens in active
disease, these antigens could not replace ESAT-6/CFP10 in
IGRAs [30,37].
The novel antigens did not identify any incident cases in
addition to those already detected by ESAT-6/CFP-10 respons-
es. Since 10 of the 14 contacts which progressed to active
disease were identified by responses to ESAT-6/CFP-10, de-
monstration of incremental prognostic power would have
necessitated the presence of responses to the novel antigens in
one or more of the four ESAT-6/CFP-10 ELISpot-negative
contacts who progressed to tuberculosis. Hence prospective
studies with a greater number of ESAT-6/CFP-10-negative
incident cases, as already observed in larger studies [22,43], are
required to fully evaluate the potential incremental value of
these novel antigens.
Although predictive values are sometimes reported in studies of
prognosis, their value is limited as they change with length of
follow-up (positive predictive values increasing and negative
predictive values decreasing as more events occur). The data
needed to compute these values is presented in table two but we
caution against their over-interpretation.
It must be noted that all children that were ,6 years old, and
children $6 years old that exhibited a positive TST result at
recruitment, or subsequently converted their TST, were given a 6-
month course of IPT in accordance with Turkish Ministry of Health
guidelines [41]. Six-months isoniazid has only 60% efficacy which
likely accounts for the substantial residual rate of progression to
tuberculosis observed in this cohort [17,44]. Since all TST-positive
individuals received IPT the prognostic value of the TST could not
be fairly assessed in this cohort [17]. Children who had T-cell
responses to the M. tuberculosis-derived antigens were also more likely
to have received IPT because of their significant association with
positive TST results [17,45]. Our results are therefore, if anything,
an underestimate of the prognostic power of specificT-cell responses
to these deleted region antigens. Given the ethical imperative
for prompt IPT in young children exposed to tuberculosis, it may
not be possible to robustly and definitively assess the true pro-
gnostic value of any test in the absence of TST-guided preventive
treatment [17].
TST conversion is a long-established reference standard for
recent M. tuberculosis infection. However, little is known about the
comparative kinetics of development of cutaneous delayed-type
hypersensitivity responses to tuberculin and circulating T-cells
specific for defined M. tuberculosis antigens early after exposure to
tuberculosis [43]. Our study illustrates the ability of ex-vivo IFN-c
T-cell responses to two of the novel antigens, Rv3873 and
Rv3879c, as well as PPD, to predict TST conversion. The fact that
T-cell responses to the novel antigens are associated with
subsequent development of a cutaneous response to tuberculin is
further evidence that they signal recent M. tuberculosis infection.
The development of IFN-c-secreting T-cell responses to ESAT-
6/CFP-10 after recent exposure is increasingly regarded as
evidence of M. tuberculosis infection, and so the relationship
between T-cell responses to the novel antigens and ESAT-6/CFP-
10-ELISpot conversion was assessed. Rv3873-specific IFN-c
responses at recruitment in ESAT-6/CFP-10-ELISpot-negative
contacts predicted subsequent development of ESAT-6/CFP-10-
specific responses. These data further support the role of Rv3873
as a specific marker of M. tuberculosis infection and also indicate
that this antigen induces an ultra-early T-cell response, preceding
responses to ESAT-6 and CFP-10 which were hitherto considered
to be the earliest antigenic targets following M. tuberculosis infection
[46,47,48,49].
Repeat TSTs and ELISpot assays were carried out between two
and six, and five and seven months post-recruitment respectively.
It is possible that some contacts were exposed to an additional
index case between initial and subsequent testing. This is unlikely
however, as the initial index cases were promptly treated, and
contact tracing immediately carried out to identify and treat all
potentially infected contacts [17,38]. In addition, exposure risk
outside the household was minimal compared to that within the
household [38].
Given that T-cell responses to Rv3879c are an important
marker of infection in active tuberculosis [30,37], it is interesting to
note that baseline Rv3879c-specific T-cell responses were not
significantly associated with progression to active disease, although
they were significantly associated with TST conversion. Con-
versely, responses to Rv3878 were predictive of progression to
active tuberculosis but not of TST conversion. The reasons for
these apparent anomalies are unclear however, it is the correlation
of responses with disease progression that is the gold standard not
correlation with TST conversion which is itself a limited and
relatively insensitive marker for progression to TB.
Interestingly, presence of a BCG scar was associated with a 67%
risk-reduction in progression to tuberculosis, consistent with its
50% protective effect in randomized trials [50]. This child cohort
has thus demonstrated the protective effect of BCG on both risk-
of-infection given exposure [38] and progression-to-disease given
infection.
We have identified T-cell responses to selected sequences from
Rv3873 and Rv3879c as early markers of M. tuberculosis infection
and responses to Rv3873 and Rv3878 as prognostic markers of
progression to tuberculosis in recently-exposed contacts. These
data suggest that the 6.4% of child contacts who were negative at
baseline to ESAT-6/CFP-10 but positive to one or more of these
three antigens may have been infected with M. tuberculosis.
However, even when including responses to the new antigens,
only a small minority (,5%) of children with positive responses
progressed to active TB, similar to the small proportion of
responders who progressed in other longitudinal studies of IGRA
in TB contacts and not substantially different to what has been
historically observed with TST. The size of the baseline interferon-
c response did not significantly differ between incident cases and
contacts that did not develop tuberculosis, suggesting that
although a positive ELISpot result is prognostic of progression to
tuberculosis, the magnitude of this response can not be used to
further refine the risk for progression [17].
Quantification of the clinical utility of these new immunological
markers will in practice depend on their incremental prognostic
power when used in combination with the conventional IGRA
antigens as well as their independent prognostic power when used
alone. Future larger prospective studies that incorporate these
novel antigens alongside ESAT-6 and CFP-10 will help to
formulate the most predictive combination of antigens to meet
the public health imperative to develop markers of LTBI with
higher predictive power than the TST and existing IGRAs.
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